#ModernA

Personalized Moderna and Merck vaccine, called intismeran, was made with same Nobel Prize-winning mRNA technology behind COVID-19 vaccines

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for melanoma patients.…

Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for melanoma patients.…

Moderna CEO Stéphane Bancel explains how mRNA, AI, and individualized care could transform everything from vaccines to cancer treatment.

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.

Why is Moderna losing billions after COVID? Stephen Ayers breaks down pipeline risks, RSV competition, cash burn, and what's next for the stock.

From Ars Technica: Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine